Syndax Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Syndax Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: New York
Headquarters state / province: New York
Headquarters country: United States
Fiscal year end: December
Ticker symbol: SNDX
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001395937
EIN: 32-0162505

Board of directors

Follow this board

Aleksandra Rizo · Director
Since 2024
Briggs Morrison · Director · President, Head of R&D
Since 2023
Dennis Podlesak · Director
Since 2023
Jennifer Jarrett · Director Overboarded
Since 2023
Keith Katkin · Director
Since 2023
Martin H. Huber Jr. · Director
Since 2023
Michael A. Metzger · Director · Chief Executive Officer
Since 2023
Pierre Legault · Director
Since 2023
William Meury · Director
Since 2023

Chief executives

Michael A. Metzger · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 10, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Pierre Legault

63.5%
Michael A. Metzger

98.9%

Board connections

7 of this board's directors also sit on 13 other boards. 13 are in the same sector.

Shared director Other board Same sector

Actuate Therapeutics Inc. Same sector
via Martin H. Huber Jr.
Arcus Biosciences Inc. Same sector
via Jennifer Jarrett
Arvinas Inc. Same sector
via Briggs Morrison
Bicycle Therapeutics plc Same sector
via Pierre Legault
CRISPR Therapeutics AG Same sector
via Briggs Morrison
Damora Therapeutics Inc. Same sector
via Jennifer Jarrett
Eledon Pharmaceuticals Inc. Same sector
via Keith Katkin
Emergent BioSolutions Inc. Same sector
via Keith Katkin
Incyte Corp. Same sector
via William Meury
Pyxis Oncology Inc. Same sector
via Michael A. Metzger
Sagimet Biosciences Inc. Same sector
via Jennifer Jarrett
Werewolf Therapeutics Inc. Same sector
via Briggs Morrison
Zura Bio Limited Same sector
via Jennifer Jarrett

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $2,862,837; 10 sales by 4 insiders

Date	Insider	Transaction	Shares	Price	Value
Oct 29, 2026	Dennis Podlesak Director	Option exercise	+8,000	$11.81	$94,480
Oct 29, 2026	Dennis Podlesak Director	Open-market sale	−8,000	$14.21	$113,716
Jul 8, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Option exercise	+32,375	$6.38	$206,553
Jul 8, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−32,375	$24.24	$784,770
Jun 12, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Option exercise	+31,235	$13.82	$431,668
Jun 12, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Open-market sale	−31,235	$18.14	$566,603
Jun 11, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Option exercise	+22,515	$13.82	$311,157
Jun 11, 2026	Botwood Nicholas A.J. Officer (Head of R&D, CMO)	Open-market sale	−34,280	$18.00	$617,040
Jun 1, 2026	Keith A. Goldan Officer (Chief Financial Officer)	Open-market sale	−1,177	$18.99	$22,351
Jun 1, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−6,847	$18.99	$130,025
Feb 9, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−17,159	$21.03	$360,854
Feb 9, 2026	Goldan Keith A. Officer (Chief Financial Officer)	Open-market sale	−3,410	$21.03	$71,712
Feb 6, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Open-market sale	−7,412	$20.62	$152,835
Feb 6, 2026	Goldan Keith A. Officer (Chief Financial Officer)	Open-market sale	−2,082	$20.62	$42,931
Feb 4, 2026	Michael A. Metzger Director, Officer (Chief Executive Officer)	Grant or award	+73,000	—	—

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Syndax Pharmaceuticals Inc.

Who is the CEO of Syndax Pharmaceuticals Inc.?

Michael A. Metzger is Syndax Pharmaceuticals Inc.'s Chief Executive Officer.

How many directors are on Syndax Pharmaceuticals Inc.'s board?

Syndax Pharmaceuticals Inc.'s board has 9 directors: Aleksandra Rizo, Briggs Morrison, Dennis Podlesak, Jennifer Jarrett, Keith Katkin, Martin H. Huber Jr., Michael A. Metzger, Pierre Legault and William Meury.

Are Syndax Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Syndax Pharmaceuticals Inc. insiders made no open-market purchases and sold $2.9 million of shares in 10 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Syndax Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="syndax-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.